Bioverativ USA Inc.

True North Therapeutics, Inc.

Genzyme Corporation

Tactic Pharma, LLC

Ipierian, Inc.

Attenuon, LLC

Graham Parry

Sandip Panicker

Nancy E Stagliano

Peter Van Vlasselaer

Stephen James Moore

Andrew P Mazar

Tony SangYoung Byun

Karen Sue Christopherson

Michael Storek

Nina C Leksa

Robert J Ternansky

Irene Griswold-Prenner

Stephanie Hopkins

Won Hyung Yoon

Patricia L Gladstone

Amy Lynn Allan

Fernando Donate

Sean M O'Hare

Marian Plunkett

Pavel A Nikitin

Tony Byun

Stephen Moore

The present disclosure provides antibodies that specifically bind complement pathway component C1s The present disclosure provides nucleic acids comprising nucleotide sequences encoding the anti-C1s antibodies; and host cells comprising the nucleic acids. The present disclosure provides compositions comprising the anti-C1s antibodies. The present disclosure provides methods of use of the anti-C1s antibodies.

Anti-C1S antibodies and methods of use thereof

The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Anti-complement C1s antibodies and uses thereof

The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies.

Humanized anti-complement factor Bb antibodies and uses thereof

The present disclosure provides anti-complement factor Bb antibodies, and compositions comprising the antibodies. The anti-Bb antibodies are useful for treating complement-mediated disorders. The present disclosure provides methods of treating complement-mediated disorders.

Anti-complement factor Bb antibodies and uses thereof

The present disclosure provides humanized anti-C1s antibodies. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the humanized anti-C1s antibodies; and host cells comprising the nucleic acids. The present disclosure provides compositions comprising the humanized anti-C1s antibodies. The present disclosure provides methods of use of the humanized anti-C1s antibodies.

Polynucleotides encoding anti-C1s antibodies

Humanized anti-complement factor Bb antibodies

The present disclosure provides methods of inducing a complement activity on a surface of a cell comprising contacting the cell with an effective amount of an anti-Factor B antibody, wherein the anti-Factor B antibody inhibits dissociation of a C3bBb complex into a Factor Bb and a C3b.

Methods of inducing complement activity

Anti-complement factor BB antibodies and uses thereof

Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage

Anti-complement C1s antibodies

Isolated tau peptides, and compositions comprising the peptides are disclosed. Further provided are antibodies specific for an isolated tau peptide. Methods of using the isolated tau peptide in diagnostic and treatment including using a pharmaceutical composition comprising the isolated tau peptide for stimulating an immune response in an individual to a tau peptide, and methods of using antibodies in detection, diagnosis, and treatment of disorders including a tauopathy are further provided.

Tau peptides, anti-tau antibodies, and methods of use thereof

Anti-complement C1s antibodies and methods of inhibiting complement C1s activity

The present disclosure provides antibodies that bind complement Cs protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Methods of inhibiting complement C4 activation with anti-complement C1s antibodies

Growing community of inventors

South San Francisco, CA, United States of America

Graham Parry